Spasticity Clinical Trial
| Verified date | May 2019 |
| Source | Sun Pharma Advanced Research Company Limited |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Open-label, safety study of SPARC1104 in subjects with spasticity due to multiple sclerosis
| Status | Completed |
| Enrollment | 375 |
| Est. completion date | October 2017 |
| Est. primary completion date | July 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 90 Years |
| Eligibility |
- Willingness to participate and give written informed consent - Men and women = 18 years of age - Sexually active women who are of child bearing potential will practice an acceptable method of birth control for the duration of the trial as judged by the investigator. Examples of acceptable contraception are: condoms, foams, jellies, diaphragm, intrauterine device, oral or long-acting injected contraceptives, bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or having a partner who is incapable of initiating conception. The practice of contraception must have started at least 3 months prior to trial entry. - If female, negative pregnancy test result at Screening - Diagnosed with MS and a known history of spasticity - Meet one of the following criteria o Subjects who completed the double-blind randomized withdrawal phase (Part 3) of trial CLR_09_21 with no major protocol violation |
| Country | Name | City | State |
|---|---|---|---|
| United States | SPARC Site 57 | Abington | Pennsylvania |
| United States | SPARC Site 16 | Albuquerque | New Mexico |
| United States | SPARC site 36 | Alexandria | Louisiana |
| United States | SPARC Site 5 | Austin | Texas |
| United States | SPARC Site 49 | Baltimore | Maryland |
| United States | SPARC Site 32 | Basalt | Colorado |
| United States | SPARC Site 21 | Baton Rouge | Louisiana |
| United States | SPARC Site 27 | Centerville | Ohio |
| United States | SPARC site 39 | Charlotte | North Carolina |
| United States | SPARC Site 26 | Clinton Township | Michigan |
| United States | SPARC Site 30 | Costa Mesa | California |
| United States | SPARC Site 60 | Dallas | Texas |
| United States | SPARC Site 5 | Denver | Colorado |
| United States | SPARC Site 7 | Derby | Connecticut |
| United States | SPARC Site 54 | Detroit | Michigan |
| United States | SPARC site 10 | Eugene | Oregon |
| United States | SPARC Site 28 | Flemington | New Jersey |
| United States | SPARC Site 29 | Foxboro | Massachusetts |
| United States | SPARC Site 22 | Fulton | Maryland |
| United States | SPARC site 4 | Gilbert | Arizona |
| United States | SPARC Site 19 | Golden Valley | Minnesota |
| United States | SPARC Site 18 | Greensboro | North Carolina |
| United States | SPARC site 47 | Hartford | Connecticut |
| United States | SPARC Site 37 | Houston | Texas |
| United States | SPARC Site 62 | Huntington | West Virginia |
| United States | SPARC Site 23 | Indian Land | South Carolina |
| United States | SPARC site 45 | Lenexa | Kansas |
| United States | SPARC Site 44 | Louisville | Kentucky |
| United States | SPARC Site 35 | Maitland | Florida |
| United States | SPARC Site 59 | Miami | Florida |
| United States | SPARC Site 58 | Milwaukee | Wisconsin |
| United States | SPARC Site 8 | New London | Connecticut |
| United States | SPARC Site 61 | New Orleans | Louisiana |
| United States | SPARC Site 14 | Newport Beach | California |
| United States | SPARC Site 6 | Ormond Beach | Florida |
| United States | SPARC Site 24 | Overland Park | Kansas |
| United States | SPARC Site 34 | Phoenix | Arizona |
| United States | SPARC Site 11 | Port Charlotte | Florida |
| United States | SPARC Site 43 | Rochester | New York |
| United States | SPARC Site 13 | Sarasota | Florida |
| United States | SPARC Site 17 | Springfield | Massachusetts |
| United States | SPARC site 38 | Springfield | Oregon |
| United States | SPARC Site 25 | Sunrise | Florida |
| United States | SPARC Site 20 | Tacoma | Washington |
| United States | SPARC Site 33 | Tampa | Florida |
| United States | SPARC Site 55 | Tampa | Florida |
| United States | SPARC Site 1 | Tucson | Arizona |
| United States | SPARC Site 50 | Washington | District of Columbia |
| United States | SPARC Site 56 | Waukesha | Wisconsin |
| United States | SPARC Site 52 | White Plains | New York |
| United States | SPARC Site 2 | Winston-Salem | North Carolina |
| Lead Sponsor | Collaborator |
|---|---|
| Sun Pharma Advanced Research Company Limited |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of Subjects With Adverse Events | 52 weeks |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06150729 -
Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Disease Activity in Pediatric Participants With Spasticity Associated With Cerebral Palsy
|
||
| Completed |
NCT02400619 -
Shockwaves Therapy and Botulinum Toxin for the Treatment of Spasticity in Patients With Cerebral Palsy. A Cross Over RCT
|
Phase 1 | |
| Completed |
NCT01945684 -
A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity
|
Phase 3 | |
| Completed |
NCT02261142 -
Efficacy and Cost-effectiveness of Spasticity Treatment With Multifocal TENS
|
N/A | |
| Completed |
NCT01444794 -
Adult Subjects Suffering From Lower Limb Spasticity Following Stroke
|
||
| Terminated |
NCT02877836 -
Functional MRI and DTI in the Preoperative Assessment of Dystonia
|
N/A | |
| Completed |
NCT02334683 -
Compare Two Guidance Techniques for Botulinum Toxin Injections for the Treatment of Limb Spasticity and Focal Dystonia
|
N/A | |
| Completed |
NCT02170779 -
Developing and Testing a Comprehensive MS Spasticity Management Program
|
Phase 2 | |
| Recruiting |
NCT05674604 -
Cryoneurolysis for Knee and Shoulder Pain in an Inpatient Setting
|
||
| Not yet recruiting |
NCT05926596 -
Leg Stretching Using an Exoskeleton on Demand for People With Spasticity
|
N/A | |
| Terminated |
NCT01712087 -
Long-term Surveillance of the MedStream Programmable Infusion System
|
||
| Completed |
NCT03906305 -
Dry Needling and Bobath Treatment Clinical Effects Focused on Stroke Patients
|
N/A | |
| Completed |
NCT03302741 -
Imaging of 3D Innervation Zone Distribution in Spastic Muscles From High-density Surface EMG Recordings
|
Phase 4 | |
| Completed |
NCT02291159 -
Effects of DNHS Technique in the Treatment of Upper Limb Spasticity and Function in Stroke
|
N/A | |
| Completed |
NCT01743651 -
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
|
Phase 3 | |
| Completed |
NCT01523210 -
DTI Study of the Influence of Physiotherapy on Distribution of BoNT in Spastic Muscle
|
N/A | |
| Completed |
NCT02073513 -
Kinesiotaping the Hand in Cerebral Palsy
|
N/A | |
| Completed |
NCT00607542 -
Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity
|
Phase 1/Phase 2 | |
| Completed |
NCT00702468 -
Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis
|
Phase 3 | |
| Active, not recruiting |
NCT04815967 -
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
|
Phase 2/Phase 3 |